BRPI0912475A2 - compostos como inibidores de quinase - Google Patents
compostos como inibidores de quinaseInfo
- Publication number
- BRPI0912475A2 BRPI0912475A2 BRPI0912475A BRPI0912475A BRPI0912475A2 BR PI0912475 A2 BRPI0912475 A2 BR PI0912475A2 BR PI0912475 A BRPI0912475 A BR PI0912475A BR PI0912475 A BRPI0912475 A BR PI0912475A BR PI0912475 A2 BRPI0912475 A2 BR PI0912475A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- kinase inhibitors
- kinase
- inhibitors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8990808P | 2008-08-19 | 2008-08-19 | |
| US61/089,908 | 2008-08-19 | ||
| US12/540,300 | 2009-08-12 | ||
| US12/540,300 US8211911B2 (en) | 2008-08-19 | 2009-08-12 | Compounds as kinase inhibitors |
| PCT/US2009/053779 WO2010021918A1 (en) | 2008-08-19 | 2009-08-13 | Compounds as kinase inhibitors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BRPI0912475A2 true BRPI0912475A2 (pt) | 2018-01-09 |
| BRPI0912475A8 BRPI0912475A8 (pt) | 2018-03-20 |
| BRPI0912475B1 BRPI0912475B1 (pt) | 2020-12-29 |
| BRPI0912475B8 BRPI0912475B8 (pt) | 2021-05-25 |
Family
ID=41696956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0912475A BRPI0912475B8 (pt) | 2008-08-19 | 2009-08-13 | compostos como inibidores de quinase, método para produção dos ditos compostos e composição farmacêutica |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8211911B2 (pt) |
| EP (1) | EP2312950B1 (pt) |
| JP (1) | JP5585892B2 (pt) |
| KR (1) | KR101727757B1 (pt) |
| CN (1) | CN102159078B (pt) |
| AU (1) | AU2009282962B2 (pt) |
| BR (1) | BRPI0912475B8 (pt) |
| CA (1) | CA2733250C (pt) |
| ES (1) | ES2617678T3 (pt) |
| IL (1) | IL210573A (pt) |
| MX (1) | MX2010011813A (pt) |
| NZ (1) | NZ590954A (pt) |
| WO (1) | WO2010021918A1 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2477723C2 (ru) | 2011-06-16 | 2013-03-20 | Общество С Ограниченной Ответственностью "Фьюжн Фарма" | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе |
| WO2013148537A1 (en) * | 2012-03-29 | 2013-10-03 | Ning Xi | Substituted spirobicyclic compounds and methods of use |
| CA2900652C (en) | 2013-02-15 | 2021-05-04 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| CN107915751A (zh) * | 2013-02-20 | 2018-04-17 | 卡拉制药公司 | 治疗性化合物和其用途 |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| WO2015066482A1 (en) | 2013-11-01 | 2015-05-07 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CN114805351B (zh) * | 2015-07-11 | 2023-05-09 | 南京爱德程医药科技有限公司 | 作为pi3k/mtor抑制剂的带有酰胺基的吡啶基取代的稠合喹啉化合物 |
| MX2019002629A (es) | 2016-09-08 | 2019-10-07 | Kala Pharmaceuticals Inc | Formas cristalinas de compuestos terapéuticos y usos de los mismos. |
| AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| AU2017324716B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CN109748902B (zh) * | 2017-11-02 | 2020-11-06 | 杭州科巢生物科技有限公司 | 一种盐酸安罗替尼的制备方法 |
| CN110357856B (zh) * | 2018-04-09 | 2021-02-26 | 新发药业有限公司 | 一种盐酸安罗替尼中间体及盐酸安罗替尼的制备方法 |
| CN115850237B (zh) * | 2018-07-24 | 2025-03-28 | 正大天晴药业集团股份有限公司 | 一种吲哚衍生物的合成方法 |
| CN108864050B (zh) * | 2018-07-25 | 2019-12-10 | 上海博璞诺科技发展有限公司 | 一种合成安罗替尼及其盐酸盐的方法 |
| CN113045559B (zh) * | 2021-03-15 | 2022-05-20 | 贵州医科大学 | 一种二芳基脲类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用 |
| US20230399313A1 (en) * | 2022-06-10 | 2023-12-14 | Advenchen Pharmaceuticals, LLC | Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4227989A1 (de) | 1992-08-21 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel |
| WO1997017329A1 (en) | 1995-11-07 | 1997-05-15 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| JP3270834B2 (ja) * | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| BRPI0017548B8 (pt) * | 1999-02-10 | 2023-05-02 | Astrazeneca Ab | Composto |
| EP1415987B1 (en) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Nitrogenous aromatic ring compounds as anti cancer agents |
| CN1688549A (zh) | 2002-08-23 | 2005-10-26 | 麒麟麦酒株式会社 | 具有TGFβ抑制活性的化合物和含所述化合物的药用组合物 |
| GB0318422D0 (en) * | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| CA2536788A1 (en) | 2003-08-29 | 2005-03-10 | Pfizer Inc. | Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents |
| JP4503022B2 (ja) | 2003-12-23 | 2010-07-14 | ファイザー・インク | 新規キノリン誘導体 |
| JP4932495B2 (ja) * | 2004-01-23 | 2012-05-16 | アムゲン インコーポレイテッド | 化合物及び使用方法 |
| CA2553433A1 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc. | Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer |
| WO2005080377A1 (ja) | 2004-02-20 | 2005-09-01 | Kirin Beer Kabushiki Kaisha | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
| WO2005097134A2 (en) | 2004-03-31 | 2005-10-20 | The Scripps Research Institute | Quinazoline based protein kinase inhibitors |
| WO2005114219A2 (en) | 2004-05-20 | 2005-12-01 | Wyeth | Assays to identify irreversibly binding inhibitors of receptor tyrosine kinases |
| AU2006277742B2 (en) | 2005-08-08 | 2010-08-26 | Pfizer Inc. | Salts and polymorphs of a VEGF-R inhibitor |
| US7977346B2 (en) * | 2006-01-17 | 2011-07-12 | Guoqing Paul Chen | Spiro compounds and methods of use |
| US8148532B2 (en) | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
-
2009
- 2009-08-12 US US12/540,300 patent/US8211911B2/en active Active
- 2009-08-13 MX MX2010011813A patent/MX2010011813A/es active IP Right Grant
- 2009-08-13 BR BRPI0912475A patent/BRPI0912475B8/pt active IP Right Grant
- 2009-08-13 JP JP2011523883A patent/JP5585892B2/ja active Active
- 2009-08-13 KR KR1020117002076A patent/KR101727757B1/ko active Active
- 2009-08-13 AU AU2009282962A patent/AU2009282962B2/en active Active
- 2009-08-13 WO PCT/US2009/053779 patent/WO2010021918A1/en not_active Ceased
- 2009-08-13 CN CN200980129433.4A patent/CN102159078B/zh active Active
- 2009-08-13 EP EP09808627.5A patent/EP2312950B1/en active Active
- 2009-08-13 NZ NZ590954A patent/NZ590954A/xx not_active IP Right Cessation
- 2009-08-13 CA CA2733250A patent/CA2733250C/en active Active
- 2009-08-13 ES ES09808627.5T patent/ES2617678T3/es active Active
-
2011
- 2011-01-11 IL IL210573A patent/IL210573A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP2312950A4 (en) | 2012-10-24 |
| KR20110044749A (ko) | 2011-04-29 |
| CA2733250A1 (en) | 2010-02-25 |
| CN102159078A (zh) | 2011-08-17 |
| WO2010021918A1 (en) | 2010-02-25 |
| WO2010021918A8 (en) | 2011-01-27 |
| AU2009282962A1 (en) | 2010-02-25 |
| JP5585892B2 (ja) | 2014-09-10 |
| JP2012500269A (ja) | 2012-01-05 |
| US8211911B2 (en) | 2012-07-03 |
| NZ590954A (en) | 2012-11-30 |
| CA2733250C (en) | 2016-06-21 |
| AU2009282962B2 (en) | 2015-10-08 |
| IL210573A (en) | 2016-05-31 |
| MX2010011813A (es) | 2010-12-01 |
| AU2009282962A8 (en) | 2011-11-10 |
| IL210573A0 (en) | 2011-03-31 |
| BRPI0912475B8 (pt) | 2021-05-25 |
| EP2312950B1 (en) | 2016-11-30 |
| ES2617678T3 (es) | 2017-06-19 |
| EP2312950A1 (en) | 2011-04-27 |
| BRPI0912475A8 (pt) | 2018-03-20 |
| BRPI0912475B1 (pt) | 2020-12-29 |
| CN102159078B (zh) | 2014-05-21 |
| KR101727757B1 (ko) | 2017-04-17 |
| US20100048599A1 (en) | 2010-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2019027I1 (el) | Παραγωγα φωσφορου ως αναστολεις κινασης | |
| BRPI0913879A2 (pt) | fenilpirazinonas como inibidores de quinase | |
| BRPI0920135A2 (pt) | imidazopiridazinacarbonitrilos úteis como inibidores de quinase | |
| BRPI0912475A8 (pt) | compostos como inibidores de quinase | |
| BRPI0913580A2 (pt) | pirrolopiridinas como inibidores de quinase | |
| BRPI0811065A2 (pt) | Indazóis 5-heteroaril substituídos como inibidores de quinase | |
| BRPI0914652A2 (pt) | compostos e composições como inibidores de quinase | |
| BRPI0906973A2 (pt) | Compostos e composições como inibidores de cinase. | |
| BRPI0908494A2 (pt) | Inibidores de pirrolopirazina quinase | |
| BRPI0912668A2 (pt) | composto e composições como inibidores de quinase | |
| BRPI0918846A2 (pt) | inibidores de cinase heterocíclica | |
| BRPI0812825A2 (pt) | Derivados ftalazinona como inibidores de parp-1 | |
| BRPI0922880A2 (pt) | compostos inibidores de quinase | |
| ATE519763T1 (de) | Pyrrolopyrazin-kinasehemmer | |
| BRPI0813499A2 (pt) | Compostos úteis como inibidores da quinase raf | |
| BRPI0906838A2 (pt) | Pirimidinas como inibidores de quinase | |
| BRPI0908849A2 (pt) | Composto e composições como c-kit e inibidores de pdgfr quinase | |
| BRPI0809974A2 (pt) | Compostos de pirimidina hidrazida como inibidores de pgds | |
| BRPI0811516A2 (pt) | Compostos e composições como inibidores de c-kit e pdgfr cinase | |
| DK2288375T3 (da) | Pegylerede insulin-lispro-forbindelser | |
| BRPI0920239A2 (pt) | compostos heterocíclicos como inibidores de proteínas quinases | |
| BRPI0920707A2 (pt) | compostos | |
| BRPI0911228A2 (pt) | compostos e composições como inibidores de proteínas quinase | |
| DK2242759T3 (da) | Forbindelser | |
| BRPI0910979A2 (pt) | compostos e composições como inibidores de quinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/12/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/08/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |